Form4insider filings, from the source

SEC Form 4 · accession 0001209191-16-096124

Evoke Pharma Inc · EVOK

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Marilyn R. Carlson
Officer — Chief Medical Officer
Period of report
Feb 5, 2016
Accepted (ET)
Feb 5, 2016 · 7:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001403708

Table I — non-derivative securities

No Table I lines on this filing.

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Stock Option (Right to Buy)F2,F1$8.67Feb 5, 2016D100,000D—Dec 1, 2023Common Stock100,0000D
Stock Option (Right to Buy)F4,F3$6.22Feb 5, 2016D45,000D—Mar 5, 2025Common Stock45,0000D
Stock Option (Right to Buy)F5$3.04Feb 5, 2016A75,000A—Dec 1, 2023Common Stock75,00075,000D
Stock Option (Right to Buy)F5$3.04Feb 5, 2016A33,750A—Mar 5, 2025Common Stock33,75033,750D

Explanation of responses